Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis - PubMed (original) (raw)
Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis
Paul Delgado-Olguín et al. Nat Genet. 2012.
Abstract
Adult-onset diseases can be associated with in utero events, but mechanisms for this remain unknown(1,2). The Polycomb histone methyltransferase Ezh2 stabilizes transcription by depositing repressive marks during development that persist into adulthood(3-9), but its function in postnatal organ homeostasis is unknown. We show that Ezh2 stabilizes cardiac gene expression and prevents cardiac pathology by repressing the homeodomain transcription factor gene Six1, which functions in cardiac progenitor cells but is stably silenced upon cardiac differentiation. Deletion of Ezh2 in cardiac progenitors caused postnatal myocardial pathology and destabilized cardiac gene expression with activation of Six1-dependent skeletal muscle genes. Six1 induced cardiomyocyte hypertrophy and skeletal muscle gene expression. Furthermore, genetically reducing Six1 levels rescued the pathology of Ezh2-deficient hearts. Thus, Ezh2-mediated repression of Six1 in differentiating cardiac progenitors is essential for stable gene expression and homeostasis in the postnatal heart. Our results suggest that epigenetic dysregulation in embryonic progenitor cells is a predisposing factor for adult disease and dysregulated stress responses.
Figures
Figure 1
Ezh2 limits cardiac growth and fibrosis. (a) Adult mice in which Ezh2 was deleted in second heart field progenitors (Ezh2fl/fl; Mef2cAHF::Cre) present hypertrophied right ventricle, with increased (b) heart weight to tibia length ratio (mg/mm), as compared to controls (Ezh2fl/fl). Ezh2fl/fl (blue bars) and Ezh2fl/fl; Mef2cAHF::Cre (red bars). (c) Wheat germ agglutinin (WGA) staining of heart sections in control (Ezh2fl/fl) or Ezh2-deficient (Ezh2fl/fl; Mef2cAHF::Cre) right ventricle (RV) and left ventricle (LV). (d) Cardiomyocyte cell surface area in Ezh2fl/fl (blue bars) or Ezh2fl/fl; Mef2cAHF::Cre (red bars) hearts. (e) Tissue disorganization and fibrosis, as revealed with Masson’s trichrome staining. In b and d, bars represent the mean +/− S.D. of measurements from at least three hearts per genotype. * indicates P < 0.05. (f) Vimentin staining of RV and LV of Ezh2fl/fl or Ezh2fl/fl; Mef2cAHF::Cre hearts. (g) Pecam staining showing invaginations of endocardium into myocardium (arrows). In f,g, the red arrow points to endocardial lining of the RV lumen. Reference bars in (a) and (e) (upper panel) = 0.5 cm; (e) (lower panel) = 100 µm; (c) = 25 µm; (f) and (g) = 100 µm.
Figure 2
Ezh2 represses expression of fetal genes, profibrosis factors and Six1. (a) QRTPCR showing relative expression of Nppa, Nppb and Myh7 mRNA. Ezh2fl/fl (blue bars) and Ezh2fl/fl; Mef2cAHF::Cre (red bars). (b) QRTPCR showing expression of Tgfβ3, Postn and Spp1. (c) Immunofluorescence showing low levels of perinuclear Tgfβ3 in control cardiomyocytes (arrows), and strong extracellular staining in the extracellular region in Ezh2fl/fl; Mef2cAHF::Cre right ventricle (RV). Nuclei were counterstained with DAPI. (d) Chromatin immunoprecipitation for Suz12, H3K27me3, RNA PolII, and acetylated histone H3 (AcH3) on the Nppa core promoter in Ezh2-deficient Hearts (red bars), as compared with controls (blue bars). e, Heat map of 1132 upregulated genes identified by RNA-seq comparing Ezh2-deficient hearts to control hearts. Numbers at left indicate fold increase. Indicated genes were amongst the most upregulated. (f) Analysis of functional categories identified a high percentage of genes regulating skeletal muscle and tissue remodelling. (g) RNA-seq analyses showed a higher percentage of deregulated genes targeted by Six1, as compared to deregulated genes not targeted by Six1, in Ezh2-deficient hearts. Reference bars = 25 µm. Bars in panels (a), (b) and (d) represent the mean +/− S.D. from at least three biological replicates. * Indicates P < 0.05.
Figure 3
Six1 is epigenetically repressed by PRC2. (a) QRTPCR showing expression of Six1 and Eya1 in embryonic and adult myocardium. (b) Upper panel: In situ hybridization showing Six1 mRNA in E13.5 Ezh2-deficient (Ezh2fl/fl; Mef2cAHF::Cre) right ventricle (RV). Reference bar = 200 µm. Lower panel. Immunofluorescence for Eya1. Cardiomyocytes were co-stained with an anti tropomyosin (Tpm1) antibody, and nuclei with DAPI. (c) Immunofluorescence for Six1 and alpha-actinin 3 (Actn3) in control (Ezh2fl/fl) and Ezh2fl/fl; Mef2cAHF::Cre adult hearts. Only Ezh2-defficient right ventricular (RV) cardiomyocytes co-expressed Six1 and Actn3. Arrows point to Six1-possitive cardiomyocyte nuclei. LV: left ventricle. Reference bar = 25 µm. (d) Chromatin immunoprecipitation for Suz12, H3K27me3, RNA PolII, and acetylated histone H3 (AcH3) on the Six1 core promoter in Ezh2-deficient Hearts (red bars), and controls (blue bars). Bars in panels (a) and (d) represent the mean +/− S.D. of at least three biological replicates. * Indicates P < 0.05.
Figure 4
Six1 has differentiated myocardium expression potential. (a) rVista plot of the percentage of conservation between the mouse (Mm) and chicken (Gg) Six1 upstream regulatory region. The indicated peak represents a highly conserved element including potential Nkx2-5, Mef2c and Gata binding motifs. (b) A LacZ reporter driven by the Hsp68 promoter and a 80bp DNA fragment including such a conserved element was injected into mouse blastocysts. (c) Lateral and frontal views of whole mount transient transgenic Six1-hsp68-lacZ embryos at E11.5 that were stained for β-galactosidase (β-gal) activity. (d) Close up of the heart from the same embryo. (e) Section from heart in g showing b-gal staining in ventricular myocardium. RA, LA, RV and LV: right and left atria, and ventricles, respectively.
Figure 5
Six1 induces cardiac hypertrophy and skeletal muscle gene expression in cardiomyocytes. (a) Cardiac myocytes infected with adenoviruses (ad) expressing control cDNA (lacZ), Six1, or Eya1, or treated with Endothelin-1. Expression of LacZ, Six1 and Eya, was confirmed with staining for β-galactosidase (β -gal), and V5-tagged Six1 and Eya1. Cardiomyocytes were stained for tropomyosin, and nuclei counterstained with DAPI. Graph shows average cell surface area. Bars represent the mean +/− S.D. from at least 100 myocytes measured. Reference bars = 10 µm. (b) QRTPCR of skeletal muscle genes on RNA from infected cardiomyocytes. Bars in (a,b) represent the mean +/− S.D. from at least three independent infections. * Indicates P < 0.05. LV: left ventricle
Figure 6
Ezh2 limits cardiac hypertrophy and fibrosis by repressing Six1. (a) Whole heart images and heart mass, as represented by heart weight to tibia length ratio of Ezh2 floxed (Ezh2fl/fl), Six1 heterozygous (Ezh2fl/fl; Six1LacZ/+), _Ezh2_-deficient mice (Ezh2fl/fl; Mef2c::Cre), and _Ezh2_-deficient mice with decreased levels of Six1 (Ezh2fl/fl; Mef2c::Cre;Six1LacZ/+) (b), Heart sections from mice with the same genotypes as in (a) stained with wheat germ agglutinin (WGA) and (c) vimentin. Graphs show the respective quantitations. (d) QRTPCR for Six1, Myh7, Myh8, Myl1, Myl4 and Actn3. Reference bars = 10 µm. Bars represent the mean +/− S.D. from at least three hearts per genotype. * indicates P < 0.05.
Comment in
- Mature cardiomyocytes recall their progenitor experience via polycomb repressive complex 2.
He A, Pu WT. He A, et al. Circ Res. 2012 Jul 6;111(2):162-4. doi: 10.1161/RES.0b013e3182635cbf. Circ Res. 2012. PMID: 22773425 No abstract available.
Similar articles
- Polycomb repressive complex 2 regulates normal development of the mouse heart.
He A, Ma Q, Cao J, von Gise A, Zhou P, Xie H, Zhang B, Hsing M, Christodoulou DC, Cahan P, Daley GQ, Kong SW, Orkin SH, Seidman CE, Seidman JG, Pu WT. He A, et al. Circ Res. 2012 Feb 3;110(3):406-15. doi: 10.1161/CIRCRESAHA.111.252205. Epub 2011 Dec 8. Circ Res. 2012. PMID: 22158708 Free PMC article. - Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy.
Papait R, Serio S, Pagiatakis C, Rusconi F, Carullo P, Mazzola M, Salvarani N, Miragoli M, Condorelli G. Papait R, et al. Circulation. 2017 Sep 26;136(13):1233-1246. doi: 10.1161/CIRCULATIONAHA.117.028561. Epub 2017 Aug 4. Circulation. 2017. PMID: 28778944 - Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells.
Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Juan AH, et al. Mol Cell. 2009 Oct 9;36(1):61-74. doi: 10.1016/j.molcel.2009.08.008. Mol Cell. 2009. PMID: 19818710 Free PMC article. - Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA, Lange CA. Simon JA, et al. Mutat Res. 2008 Dec 1;647(1-2):21-9. doi: 10.1016/j.mrfmmm.2008.07.010. Epub 2008 Aug 3. Mutat Res. 2008. PMID: 18723033 Review. - EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases.
Yuan JL, Yin CY, Li YZ, Song S, Fang GJ, Wang QS. Yuan JL, et al. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):192-201. doi: 10.1097/FJC.0000000000001062. J Cardiovasc Pharmacol. 2021. PMID: 34029268 Review.
Cited by
- Epigenetic Regulation of Mammalian Cardiomyocyte Development.
Mensah IK, Gowher H. Mensah IK, et al. Epigenomes. 2024 Jun 29;8(3):25. doi: 10.3390/epigenomes8030025. Epigenomes. 2024. PMID: 39051183 Free PMC article. Review. - KDM8 epigenetically controls cardiac metabolism to prevent initiation of dilated cardiomyopathy.
Ahmed A, Syed JN, Chi L, Wang Y, Perez-Romero C, Lee D, Kocaqi E, Caballero A, Yang J, Escalante-Covarrubias Q, Ishimura A, Suzuki T, Aguilar-Arnal L, Gonzales GB, Kim KH, Delgado-Olguín P. Ahmed A, et al. Nat Cardiovasc Res. 2023;2(2):174-191. doi: 10.1038/s44161-023-00214-0. Epub 2023 Feb 13. Nat Cardiovasc Res. 2023. PMID: 38665902 Free PMC article. - Chromatin modifiers in human disease: from functional roles to regulatory mechanisms.
Nie Y, Song C, Huang H, Mao S, Ding K, Tang H. Nie Y, et al. Mol Biomed. 2024 Apr 8;5(1):12. doi: 10.1186/s43556-024-00175-1. Mol Biomed. 2024. PMID: 38584203 Free PMC article. Review. - Research advances of polycomb group proteins in regulating mammalian development.
Li Y, Mo Y, Chen C, He J, Guo Z. Li Y, et al. Front Cell Dev Biol. 2024 Mar 5;12:1383200. doi: 10.3389/fcell.2024.1383200. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38505258 Free PMC article. Review. - Cfp1 Controls Cardiomyocyte Maturation by Modifying Histone H3K4me3 of Structural, Metabolic, and Contractile Related Genes.
Li C, Zhang Y, Shen J, Bao H, Zhao Y, Li D, Li S, Liu Y, Yang J, Zhou Z, Gao K, Zhao L, Pei Y, Lu Y, Pan Z, Cai B. Li C, et al. Adv Sci (Weinh). 2024 Mar;11(11):e2305992. doi: 10.1002/advs.202305992. Epub 2024 Jan 9. Adv Sci (Weinh). 2024. PMID: 38196272 Free PMC article.
References
- Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nature reviews. Endocrinology. 2009;5:401–408. - PubMed
- Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature. 2010;465:721–727. - PubMed
- Surface LE, Thornton SR, Boyer LA. Polycomb group proteins set the stage for early lineage commitment. Cell stem cell. 2010;7:288–298. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL098179/HL/NHLBI NIH HHS/United States
- U01HL098166/HL/NHLBI NIH HHS/United States
- U01HL098179/HL/NHLBI NIH HHS/United States
- C06 RR018928/RR/NCRR NIH HHS/United States
- U01 HL098179-04/HL/NHLBI NIH HHS/United States
- U01 HL098179-01/HL/NHLBI NIH HHS/United States
- U01 HL098179-02/HL/NHLBI NIH HHS/United States
- U01 HL098179-03/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous